GLP Watchdog

MEDVi vs Noom

MEDVi has an open FDA warning letter dated February 20, 2026. Noom has none. On compounded semaglutide injection, Noom costs $240 less a year at standing rates: $179 a month against $199 a month at MEDVi.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

MEDVi / Noom

MEDVi logo

MEDVi

7.7/10

Noom logo

Noom

5.8/10

FDA warning letters
None on record
Pharmacy
None named in our record
Lowest standing price
$199/moCompounded semaglutide injection
$179/moCompounded semaglutide injection
States
All 50 states
No state list published
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit MEDVi
Visit Noom

Neither MEDVi nor Noom pays us. Links to them earn nothing. Scores: MEDVi 7.7, Noom 5.8. How we are paid

What the record shows

  1. 01

    MEDVi has an open FDA warning letter dated February 20, 2026. Noom has none.

  2. 02

    MEDVi names three pharmacies, all 503A. Noom names no compounding pharmacy in our record.

  3. 03

    On compounded semaglutide injection, Noom costs $240 less a year at standing rates: $179 a month against $199 a month at MEDVi.

  4. 04

    Only Noom lists a price for brand-name tirzepatide pen.

  5. 05

    MEDVi lists all 50 states. Noom publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

MEDVi

Noom

Compounded semaglutide injection

$199/mo

$2,388 a year

$179/moLower

$2,148 a year

Brand-name tirzepatide pen
Not sold or not priced

$349/mo

$4,188 a year

Price includes
Medication, clinician visits, shipping, coaching
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None; billed monthly
Not stated
Refunds
Full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed
Refunds only before a prescription is written; renewal charges are not refunded
Early-exit fee
None stated
Not stated

Read off each seller’s own pages. MEDVi: October 25, 2026. Noom: October 30, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for MEDVi

7.7/10
  • Names its compounding pharmacy
  • Open FDA warning letter, February 20, 2026
Visit MEDVi

The case for Noom

5.8/10
  • No FDA warning letter on record
  • $240 a year less on compounded semaglutide injection
  • Sells brand-name tirzepatide pen, which MEDVi does not price
  • Names no compounding pharmacy
  • Publishes no state list
Visit Noom

Scores

MEDVi 7.7 · Noom 5.8 out of 10. Six weighted parts.

Value25%

5.0A
vs
B
0.9

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
6.5

Accessibility10%

10.0A
vs
B
5.0

Support10%

8.5A
vs
B
4.0

The score is the same formula for every seller. Payment does not enter it. Method

MEDVi vs Noom: questions

MEDVi has an open FDA warning letter dated February 20, 2026. Noom has none. Letters are matched to a seller by company, domain and address, never by a similar name.
MEDVi names three pharmacies, all 503A. Noom names no compounding pharmacy in our record. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
Noom, by $240 a year at standing rates. MEDVi: $199 a month, about $2,388 a year. Noom: $179 a month, about $2,148 a year.
MEDVi states you can cancel at any time; refunds: full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed. Noom states you can cancel at any time; refunds: refunds only before a prescription is written; renewal charges are not refunded.
Neither MEDVi nor Noom pays us. Links to them earn nothing. Scores: MEDVi 7.7, Noom 5.8.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks